Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EndoTAG-1: Final Phase II data

Final data from an investigator-initiated Phase II trial in 15 patients with non-metastatic HER2-negative breast cancer showed that once-weekly 22 mg/m 2 EndoTAG-1 plus 70 mg/m 2 paclitaxel as neoadjuvant therapy led

Read the full 325 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE